<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Biomed Res</journal-id><journal-id journal-id-type="iso-abbrev">Adv Biomed Res</journal-id><journal-id journal-id-type="publisher-id">ABR</journal-id><journal-title-group><journal-title>Advanced Biomedical Research</journal-title></journal-title-group><issn pub-type="epub">2277-9175</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28217642</article-id><article-id pub-id-type="pmc">5220753</article-id><article-id pub-id-type="publisher-id">ABR-5-204</article-id><article-id pub-id-type="doi">10.4103/2277-9175.196831</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Immediate outcomes of eptifibatide therapy during intracoronary stent implantation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shariati</surname><given-names>Hooman</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Sanei</surname><given-names>Hamid</given-names></name><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Pourmoghadas</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Salehizadeh</surname><given-names>Leila</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Amirpour</surname><given-names>Afshin</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib></contrib-group><aff id="aff1">Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff2"><label>1</label>Interventional Cardiologist, Chamran Hospital, Isfahan University of Medical Sciences, Isfahan, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Hamid Sanei, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: <email xlink:href="h_sanei@med.mui.ac.ir">h_sanei@med.mui.ac.ir</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>27</day><month>12</month><year>2016</year></pub-date><volume>5</volume><elocation-id>204</elocation-id><history><date date-type="received"><day>25</day><month>6</month><year>2013</year></date><date date-type="accepted"><day>15</day><month>10</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: © 2016 Advanced Biomedical Research</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="3587" xml_f="3598" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="3609" xml_f="3751" txt_i="23" txt_f="165">The objective of the present study was to assess the major immediate outcomes of eptifibatide therapy during intracoronary stent implantation.</offsets></p></sec><sec id="st2"><title><offsets xml_i="3782" xml_f="3804" txt_i="167" txt_f="189">Materials and Methods:</offsets></title><p><offsets xml_i="3815" xml_f="3950" txt_i="190" txt_f="325">In an interventional study, patients undergoing percutaneous coronary intervention (PCI) were randomized into either the eptifibatide (</offsets><italic><offsets xml_i="3958" xml_f="3959" txt_i="325" txt_f="326">n</offsets></italic><offsets xml_i="3968" xml_f="3992" txt_i="326" txt_f="350"> = 100) or the control (</offsets><italic><offsets xml_i="4000" xml_f="4001" txt_i="350" txt_f="351">n</offsets></italic><offsets xml_i="4010" xml_f="4309" txt_i="351" txt_f="650"> = 107) group. In each group, demographic and clinical characteristics such as cardiac death, stent thrombosis (ST), myocardial infarction (MI), rates of target lesion and vessel revascularization, cerebral vascular accident (CVA), and emergency coronary artery bypass grafting (CABG) were recorded.</offsets></p></sec><sec id="st3"><title><offsets xml_i="4340" xml_f="4348" txt_i="652" txt_f="660">Results:</offsets></title><p><offsets xml_i="4359" xml_f="4658" txt_i="661" txt_f="960">The overall rates of major adverse events such as mortality, Stent thrombosis (ST), Myocardial Infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), CVA, and emergency CABG within 24 h after stent implantation were low and comparable between the two groups; </offsets><italic><offsets xml_i="4666" xml_f="4667" txt_i="960" txt_f="961">P</offsets></italic><offsets xml_i="4676" xml_f="4730" txt_i="961" txt_f="1012"> &gt; 0.05 considered significant for all comparisons.</offsets></p></sec><sec id="st4"><title><offsets xml_i="4761" xml_f="4772" txt_i="1014" txt_f="1025">Conclusion:</offsets></title><p><offsets xml_i="4783" xml_f="4993" txt_i="1026" txt_f="1236">There were no statistical differences between the clinical outcomes of groups administered with single-dose intracoronary eptifibatide and control groups among patients undergoing PCI during stent implantation.</offsets></p></sec></abstract><kwd-group><kwd>Eptifibatide</kwd><kwd>immediate clinical outcome</kwd><kwd>percutaneous coronary intervention</kwd><kwd>stent implantation</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title><offsets xml_i="5241" xml_f="5253" txt_i="1245" txt_f="1257">INTRODUCTION</offsets></title><p><offsets xml_i="5264" xml_f="5384" txt_i="1258" txt_f="1378">Coronary heart disease (CHD) is the narrowing or blockage of the coronary arteries generally caused by atherosclerosis.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="5417" xml_f="5418" txt_i="1378" txt_f="1379">1</offsets></xref><offsets xml_i="5425" xml_f="5587" txt_i="1379" txt_f="1541">] The outreach of stents has been a notable progress in the treatment of obstructive coronary artery disease (CAD) since the introduction of balloon angioplasty.[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="5620" xml_f="5621" txt_i="1541" txt_f="1542">2</offsets></xref><offsets xml_i="5628" xml_f="5876" txt_i="1542" txt_f="1790">] Significant reduction in outcomes of mortality, myocardial infarction (MI), and target vessel revascularization (TVR) using parenteral glycoprotein IIb/IIIa receptor antagonists has been widely reported for patients with acute coronary syndrome.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="5909" xml_f="5910" txt_i="1790" txt_f="1791">3</offsets></xref><xref rid="ref4" ref-type="bibr"><offsets xml_i="5950" xml_f="5951" txt_i="1791" txt_f="1792">4</offsets></xref><xref rid="ref5" ref-type="bibr"><offsets xml_i="5991" xml_f="5992" txt_i="1792" txt_f="1793">5</offsets></xref><xref rid="ref6" ref-type="bibr"><offsets xml_i="6032" xml_f="6033" txt_i="1793" txt_f="1794">6</offsets></xref><offsets xml_i="6040" xml_f="6243" txt_i="1794" txt_f="1997">] Glycoprotein IIb/IIIa receptor antagonists consist of: The monoclonal antibody abciximab, the peptide receptor antagonist eptifibatide, and the nonpeptide receptor antagonists tirofiban and lamifiban.[</offsets><xref rid="ref7" ref-type="bibr"><offsets xml_i="6276" xml_f="6277" txt_i="1997" txt_f="1998">7</offsets></xref><offsets xml_i="6284" xml_f="6392" txt_i="1998" txt_f="2106">] Among them eptifibatide (Integrilin) is often less expensive and more widely available in many hospitals.[</offsets><xref rid="ref8" ref-type="bibr"><offsets xml_i="6425" xml_f="6426" txt_i="2106" txt_f="2107">8</offsets></xref><xref rid="ref9" ref-type="bibr"><offsets xml_i="6466" xml_f="6467" txt_i="2107" txt_f="2108">9</offsets></xref><offsets xml_i="6474" xml_f="6653" txt_i="2108" txt_f="2287">] Eptifibatide has been shown to ameliorate cardiac outcomes in patients with percutaneous coronary intervention (PCI) by lessening the incidence of major adverse cardiac events.[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="6687" xml_f="6689" txt_i="2287" txt_f="2289">10</offsets></xref><xref rid="ref11" ref-type="bibr"><offsets xml_i="6730" xml_f="6732" txt_i="2289" txt_f="2291">11</offsets></xref><xref rid="ref12" ref-type="bibr"><offsets xml_i="6773" xml_f="6775" txt_i="2291" txt_f="2293">12</offsets></xref><offsets xml_i="6782" xml_f="7318" txt_i="2293" txt_f="2829">] In an investigation, the complementary effect of thienopyridine pretreatment and the integrin blockade in coronary stent intervention were assessed; according to their results, pretreatment with thienopyridine decreased the rate of ischemic complications regardless of eptifibatide treatment. They expressed that the efficacy of eptifibatide is dependant on the presence of a loading dose of thienopyridine administration. Also, optimal outcomes were attained by receiving thienopyridine pretreatment along with eptifibatide therapy.[</offsets><xref rid="ref13" ref-type="bibr"><offsets xml_i="7352" xml_f="7354" txt_i="2829" txt_f="2831">13</offsets></xref><offsets xml_i="7361" xml_f="7689" txt_i="2831" txt_f="3159">] In a study conducted between January 2003 and August 2005, the long-term mortality after bolus-only administration of abciximab, eptifibatide, and tirofiban during PCI were evaluated. As is shown in their results, eptifibatide was able to ameliorate long-term survival prognosis compared to abciximab when applied bolus-only.[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="7723" xml_f="7725" txt_i="3159" txt_f="3161">14</offsets></xref><offsets xml_i="7732" xml_f="7741" txt_i="3161" txt_f="3170">] O’Shea </offsets><italic><offsets xml_i="7749" xml_f="7754" txt_i="3170" txt_f="3175">et al</offsets></italic><offsets xml_i="7763" xml_f="8034" txt_i="3175" txt_f="3446">. in a randomized controlled trial (RCT) entitled “Platelet glycoprotein IIb/IIIa Integrin blockade with Eptifibatide in coronary stent intervention” showed that adjunctive eptifibatide therapy during coronary stent implantation is beneficial within a 6-month follow-up.[</offsets><xref rid="ref15" ref-type="bibr"><offsets xml_i="8068" xml_f="8070" txt_i="3446" txt_f="3448">15</offsets></xref><offsets xml_i="8077" xml_f="8385" txt_i="3448" txt_f="3756">] Intracoronary Eptifibatide bolus administration during PCI in patients with acute coronary syndromes indicated a higher local platelet glycoprotein IIb/IIIa receptor occupancy, which is related to improved microvascular perfusion demonstrated by improving the corrected thrombolysis in the MI frame count.[</offsets><xref rid="ref16" ref-type="bibr"><offsets xml_i="8419" xml_f="8421" txt_i="3756" txt_f="3758">16</offsets></xref><offsets xml_i="8428" xml_f="8718" txt_i="3758" txt_f="4048">] In an investigation, different outcomes concerning the use of eptifibatide instead of abciximab in patients undergoing primary PCI were assessed. There were no differences expressed in the early outcomes of patients treated with eptifibatide, compared to patients treated with abciximab.[</offsets><xref rid="ref8" ref-type="bibr"><offsets xml_i="8751" xml_f="8752" txt_i="4048" txt_f="4049">8</offsets></xref><offsets xml_i="8759" xml_f="9240" txt_i="4049" txt_f="4530">] Also, in another survey the clinical outcomes of eptifibatide and abciximab in acute ST elevation MI (STEMI) patients undergoing PCI were compared; no significant differences were observed in clinical outcomes between STEMI patients treated with eptifibatide or abciximab. It has been suggested that because of the lower cost of eptifibatide, it can be a suitable substitute for abciximab and reduce the overall medication costs while maintaining beneficial safety and efficacy.[</offsets><xref rid="ref17" ref-type="bibr"><offsets xml_i="9274" xml_f="9276" txt_i="4530" txt_f="4532">17</offsets></xref><offsets xml_i="9283" xml_f="9676" txt_i="4532" txt_f="4925">] Although eptifibatide has been fairly studied in patients with CAD, there are few available data in the case of a single dose (10 cc) injection prior to coronary stent implantation to justify its use in PCI. The objective of the present study was to evaluate the effect of eptifibatide before intracoronary stent implantation on immediate outcomes in patients with CAD in a double-blind RCT.</offsets></p></sec><sec sec-type="materials|methods" id="sec1-2"><title><offsets xml_i="9739" xml_f="9760" txt_i="4927" txt_f="4948">MATERIALS AND METHODS</offsets></title><p><offsets xml_i="9771" xml_f="9947" txt_i="4949" txt_f="5125">The design of this study was a single-center, double-blind RCT comparing eptifibatide plus stenting with stenting alone in 207 patients during intracoronary stent implantation.</offsets></p><p><offsets xml_i="9954" xml_f="10313" txt_i="5126" txt_f="5485">The study was conducted between January and December 2012 and performed in an educational hospital (Shahid-Chamran hospital, Isfahan, Iran). The intervention protocol was approved by the Ethics Committee of the Isfahan University of Medical Sciences, and all patients provided written informed consent. The nonprobability consecutive sampling method was used.</offsets></p><p><offsets xml_i="10320" xml_f="10433" txt_i="5486" txt_f="5599">All patients were randomly divided into one of the two groups by Random Allocation Software (SPSS Inc. Chicago).[</offsets><xref rid="ref18" ref-type="bibr"><offsets xml_i="10467" xml_f="10469" txt_i="5599" txt_f="5601">18</offsets></xref><offsets xml_i="10476" xml_f="10612" txt_i="5601" txt_f="5737">] According to the randomization protocol, eptifibatide (150 µg/kg) was administered in 107 patients just before the stenting procedure.</offsets></p><p><offsets xml_i="10619" xml_f="10920" txt_i="5738" txt_f="6039">The inclusion criteria were: Age 30-75 years, stable or unstable angina and/or documentation of myocardial ischemia attributable to coronary artery stenosis, patients without renal failure (renal failure defined as a serum creatinine ≥2 mg/dl), and patients without any infectious or systemic disease.</offsets></p><p><offsets xml_i="10927" xml_f="11145" txt_i="6040" txt_f="6258">It was decided that cardiac death, stent thrombosis (ST), MI, rates of target lesion and vessel revascularization, cerebral vascular accident (CVA), and emergency CABG would be the major endpoints of the present study.</offsets></p><p><offsets xml_i="11152" xml_f="11364" txt_i="6259" txt_f="6471">MI will be distinguished as Q wave or non-Q wave (defined as elevation of total creatine kinase [CK] two times above the upper limit of normal with a positive MB fraction in the absence of pathological Q waves).[</offsets><xref rid="ref19" ref-type="bibr"><offsets xml_i="11398" xml_f="11400" txt_i="6471" txt_f="6473">19</offsets></xref><offsets xml_i="11407" xml_f="11626" txt_i="6473" txt_f="6692">] Target lesion revascularization (TLR) is defined as any revascularization performed on the treated segment and target vessel revascularization (TVR) as any percutaneous reintervention performed on the treated vessel.[</offsets><xref rid="ref20" ref-type="bibr"><offsets xml_i="11660" xml_f="11662" txt_i="6692" txt_f="6694">20</offsets></xref><offsets xml_i="11669" xml_f="11806" txt_i="6694" txt_f="6831">] Urgent or emergency CABG is defined as a surgical procedure immediately following catheterization, mandated by clinical circumstances.[</offsets><xref rid="ref21" ref-type="bibr"><offsets xml_i="11840" xml_f="11842" txt_i="6831" txt_f="6833">21</offsets></xref><offsets xml_i="11849" xml_f="12068" txt_i="6833" txt_f="7049">] Acute coronary ST, defined as ST within 30 days of deployment, has been reduced to &lt;1-2% as a result of improved deployment techniques that fully appose stent to the vessel wall and the use of antiplatelet agents.[</offsets><xref rid="ref22" ref-type="bibr"><offsets xml_i="12102" xml_f="12104" txt_i="7049" txt_f="7051">22</offsets></xref><offsets xml_i="12111" xml_f="12112" txt_i="7051" txt_f="7052">]</offsets></p><p><offsets xml_i="12119" xml_f="12288" txt_i="7053" txt_f="7222">All data were analyzed using PASW 18.0 (SPSS Inc., Chicago, IL, USA). Data are presented as Mean ± SD for continuous variables and number (percent) for categorical ones.</offsets></p><p><offsets xml_i="12295" xml_f="12384" txt_i="7223" txt_f="7312">We used the Kolmogorov-Smirnov test for normality in order to evaluate the assumption of </offsets><italic><offsets xml_i="12392" xml_f="12393" txt_i="7312" txt_f="7313">t</offsets></italic><offsets xml_i="12402" xml_f="12497" txt_i="7313" txt_f="7408">-test. Statistical differences between studied groups were assessed by the independent-samples </offsets><italic><offsets xml_i="12505" xml_f="12506" txt_i="7408" txt_f="7409">t</offsets></italic><offsets xml_i="12515" xml_f="12568" txt_i="7409" txt_f="7462">-test, the Chi-square test, and Fisher's exact test. </offsets><italic><offsets xml_i="12576" xml_f="12577" txt_i="7462" txt_f="7463">P</offsets></italic><offsets xml_i="12586" xml_f="12630" txt_i="7463" txt_f="7504"> &lt; 0.05 denoted statistical significance.</offsets></p></sec><sec sec-type="results" id="sec1-3"><title><offsets xml_i="12683" xml_f="12690" txt_i="7506" txt_f="7513">RESULTS</offsets></title><p><offsets xml_i="12701" xml_f="12743" txt_i="7514" txt_f="7556">The flow-diagram of the study is shown in </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="12773" xml_f="12781" txt_i="7556" txt_f="7564">Figure 1</offsets></xref><offsets xml_i="12788" xml_f="13056" txt_i="7564" txt_f="7832">. A total of 110 males (53.1%) and 97 females (46.9%) were included in the analysis. The mean age of the participants was 61.1 ± 8.6 years (range, 45-87 years), and there were no significant statistical differences in age and sex distributions between the two groups (</offsets><italic><offsets xml_i="13064" xml_f="13065" txt_i="7832" txt_f="7833">P</offsets></italic><offsets xml_i="13074" xml_f="13086" txt_i="7833" txt_f="7845"> = 0.81 and </offsets><italic><offsets xml_i="13094" xml_f="13095" txt_i="7845" txt_f="7846">P</offsets></italic><offsets xml_i="13104" xml_f="13242" txt_i="7846" txt_f="7984"> = 0.97, respectively). The demographic and clinical characteristics of the study population categorized by groups are shown in detail in </offsets><xref ref-type="table" rid="T1"><offsets xml_i="13274" xml_f="13281" txt_i="7984" txt_f="7991">Table 1</offsets></xref><offsets xml_i="13288" xml_f="13289" txt_i="7991" txt_f="7992">.</offsets></p><fig id="F1" position="float"><label><offsets xml_i="13330" xml_f="13338" txt_i="7993" txt_f="8001">Figure 1</offsets></label><caption><p><offsets xml_i="13358" xml_f="13383" txt_i="8001" txt_f="8026">Flow diagram of the study</offsets></p></caption><graphic xlink:href="ABR-5-204-g001"></graphic></fig><table-wrap id="T1" position="float"><label><offsets xml_i="13494" xml_f="13501" txt_i="8027" txt_f="8034">Table 1</offsets></label><caption><p><offsets xml_i="13521" xml_f="13615" txt_i="8034" txt_f="8128">Demographic features and immediate clinical outcomes of 207 patients divided by studied groups</offsets></p></caption><graphic xlink:href="ABR-5-204-g002"></graphic></table-wrap><p><offsets xml_i="13692" xml_f="13846" txt_i="8129" txt_f="8283">As is shown in the table, the frequency of smoking, hypertension, family history of CAD, prior MI, and hyperlipidemia were not statistically significant (</offsets><italic><offsets xml_i="13854" xml_f="13855" txt_i="8283" txt_f="8284">P</offsets></italic><offsets xml_i="13864" xml_f="13876" txt_i="8284" txt_f="8293"> &gt; 0.05).</offsets></p><p><offsets xml_i="13883" xml_f="14008" txt_i="8294" txt_f="8419">The frequency of diabetes mellitus (DM) in the case group was significantly higher than that in the controls (42% vs. 21.5%; </offsets><italic><offsets xml_i="14016" xml_f="14017" txt_i="8419" txt_f="8420">P</offsets></italic><offsets xml_i="14026" xml_f="14036" txt_i="8420" txt_f="8430"> = 0.001).</offsets></p><p><offsets xml_i="14043" xml_f="14271" txt_i="8431" txt_f="8659">In this study we did not find any significant to statistical differences between the eptifibatide group and the control group in clinical outcomes such as cardiac and noncardiac death, ST, MI, TLR, TVR, CVA, and emergency CABG (</offsets><italic><offsets xml_i="14279" xml_f="14280" txt_i="8659" txt_f="8660">P</offsets></italic><offsets xml_i="14289" xml_f="14301" txt_i="8660" txt_f="8669"> &gt; 0.05).</offsets></p></sec><sec sec-type="discussion" id="sec1-4"><title><offsets xml_i="14357" xml_f="14367" txt_i="8671" txt_f="8681">DISCUSSION</offsets></title><p><offsets xml_i="14378" xml_f="14601" txt_i="8682" txt_f="8905">Our study examined the clinical immediate outcomes in a consecutive series of patients with CAD who underwent primary PCI and received eptifibatide plus stenting, or stenting alone as a control group, in a double-blind RCT.</offsets></p><p><offsets xml_i="14608" xml_f="14836" txt_i="8906" txt_f="9134">The principal finding of the present investigation is that in the studied population of patients with CAD, single-dose intracoronary eptifibatide plus stenting result in similar clinical outcomes when compared to stenting alone.</offsets></p><p><offsets xml_i="14843" xml_f="14887" txt_i="9135" txt_f="9179">In accordance with our findings, Raveendran </offsets><italic><offsets xml_i="14895" xml_f="14900" txt_i="9179" txt_f="9184">et al</offsets></italic><offsets xml_i="14909" xml_f="15062" txt_i="9184" txt_f="9337">. in an observational analysis conducted between January 1999 and January 2004 compared the clinical outcomes of 576 patients treated with eptifibatide (</offsets><italic><offsets xml_i="15070" xml_f="15071" txt_i="9337" txt_f="9338">n</offsets></italic><offsets xml_i="15080" xml_f="15102" txt_i="9338" txt_f="9360"> = 249) or abciximab (</offsets><italic><offsets xml_i="15110" xml_f="15111" txt_i="9360" txt_f="9361">n</offsets></italic><offsets xml_i="15120" xml_f="15467" txt_i="9361" txt_f="9708"> = 327) during primary PCI. As they noted, there were no significant differences between the outcomes of in-hospital death or MI in both eptifibatide- and abciximab-treated groups. They also remarked that eptifibatide was useful and safe as adjunctive pharmacotherapy for patients undergoing primary PCI for acute MI in comparison with abciximab.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="15500" xml_f="15501" txt_i="9708" txt_f="9709">3</offsets></xref><offsets xml_i="15508" xml_f="15644" txt_i="9709" txt_f="9845">] In an investigation done between October 2002 and July 2006, different outcomes of 3,541 patients concerning the use of eptifibatide (</offsets><italic><offsets xml_i="15652" xml_f="15653" txt_i="9845" txt_f="9846">n</offsets></italic><offsets xml_i="15662" xml_f="15694" txt_i="9846" txt_f="9878"> = 2,812) instead of abciximab (</offsets><italic><offsets xml_i="15702" xml_f="15703" txt_i="9878" txt_f="9879">n</offsets></italic><offsets xml_i="15712" xml_f="15935" txt_i="9879" txt_f="10102"> = 729) undergoing primary PCI were assessed. As their results indicated, there were no significant differences in case of early outcomes of patients treated with eptifibatide compared with patients treated with abciximab.[</offsets><xref rid="ref8" ref-type="bibr"><offsets xml_i="15968" xml_f="15969" txt_i="10102" txt_f="10103">8</offsets></xref><offsets xml_i="15976" xml_f="16022" txt_i="10103" txt_f="10149">] Also, in a study published in 2002 by Stone </offsets><italic><offsets xml_i="16030" xml_f="16035" txt_i="10149" txt_f="10154">et al</offsets></italic><offsets xml_i="16044" xml_f="16347" txt_i="10154" txt_f="10457">., upon 2,082 patients with acute MI and in a comparison of angioplasty with stenting, with or without abciximab, no significant differences were observed between the percutaneous transluminal coronary angioplasty plus abciximab, stenting alone, or stenting plus abciximab cohorts at 30 days follow-up.[</offsets><xref rid="ref23" ref-type="bibr"><offsets xml_i="16381" xml_f="16383" txt_i="10457" txt_f="10459">23</offsets></xref><offsets xml_i="16390" xml_f="16440" txt_i="10459" txt_f="10509">] The incorporation of the results given by Stone </offsets><italic><offsets xml_i="16448" xml_f="16453" txt_i="10509" txt_f="10514">et al</offsets></italic><offsets xml_i="16462" xml_f="16579" txt_i="10514" txt_f="10631">. and reports that indicated similar outcomes for eptifibatide and abciximab could be a confirmation of our findings.</offsets></p><p><offsets xml_i="16586" xml_f="16959" txt_i="10632" txt_f="11005">The Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) indicated the efficacy of adjunctive eptifibatide therapy during coronary stent implantation at 48 h and at 30 days follow-up. Secondary studies proved the benefits of eptifibatide upon composite rates of death or MI and death, infarction, or TVR during 6 and 12 months follow-up.[</offsets><xref rid="ref11" ref-type="bibr"><offsets xml_i="16993" xml_f="16995" txt_i="11005" txt_f="11007">11</offsets></xref><xref rid="ref15" ref-type="bibr"><offsets xml_i="17036" xml_f="17038" txt_i="11007" txt_f="11009">15</offsets></xref><xref rid="ref24" ref-type="bibr"><offsets xml_i="17079" xml_f="17081" txt_i="11009" txt_f="11011">24</offsets></xref><offsets xml_i="17088" xml_f="17089" txt_i="11011" txt_f="11012">]</offsets></p><p><offsets xml_i="17096" xml_f="17279" txt_i="11013" txt_f="11196">Although several studies have shown obvious reduction in a variety of ischemic events in patients, which results from receiving eptifibatide as adjunctive pharmacotherapy during PCI,[</offsets><xref rid="ref25" ref-type="bibr"><offsets xml_i="17313" xml_f="17315" txt_i="11196" txt_f="11198">25</offsets></xref><xref rid="ref26" ref-type="bibr"><offsets xml_i="17356" xml_f="17358" txt_i="11198" txt_f="11200">26</offsets></xref><offsets xml_i="17365" xml_f="17975" txt_i="11200" txt_f="11810">] in our results we could not find any significant differences concerning the effect of eptifibatide upon clinical outcomes compared with the control group. The failure to reach any statistical significance between the two groups (eptifibatide and control), despite the differences reported by former studies, may be related to the small sample size, which greatly reduced the power of the statistical analyses, or to the relatively short time of follow-up. Some supplementary studies with larger sample sizes and more follow-up time are needed to evaluate the real effect of eptifibatide on clinical outcomes.</offsets></p></sec><sec sec-type="conclusion" id="sec1-5"><title><offsets xml_i="18031" xml_f="18041" txt_i="11812" txt_f="11822">CONCLUSION</offsets></title><p><offsets xml_i="18052" xml_f="18437" txt_i="11823" txt_f="12208">We could not find any significant statistical differences between the short-term clinical outcomes of the single-dose intracoronary eptifibatide and control groups in patients undergoing primary PCI during stent implantation. On the other hand, the use of eptifibatide before intracoronary stent implantation did not have any positive effect on immediate outcomes in patients with CAD.</offsets></p><sec id="sec2-1"><title><offsets xml_i="18465" xml_f="18498" txt_i="12209" txt_f="12242">Financial support and sponsorship</offsets></title><p><offsets xml_i="18509" xml_f="18513" txt_i="12243" txt_f="12247">Nil.</offsets></p></sec><sec id="sec2-2" sec-type="COI-statement"><title><offsets xml_i="18572" xml_f="18593" txt_i="12249" txt_f="12270">Conflicts of interest</offsets></title><p><offsets xml_i="18604" xml_f="18639" txt_i="12271" txt_f="12306">There are no conflicts of interest.</offsets></p></sec></sec></body><back><ack><title>Acknowledgements</title><p>The study was supported by Vice Chancellor for Research (School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran) [Project number: 391460].</p></ack><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skoog</surname><given-names>M</given-names></name><name><surname>Grevstad</surname><given-names>B</given-names></name><name><surname>Wetterslev</surname><given-names>J</given-names></name><name><surname>Hróbjartsson</surname><given-names>A</given-names></name><name><surname>Gluud</surname><given-names>C</given-names></name></person-group><article-title>Antibiotics for secondary prevention of coronary heart disease</article-title><source>The Cochrane Library</source><year>2013</year></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Htay</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>MW</given-names></name></person-group><article-title>Drug-eluting stent: A review and update</article-title><source>Vasc Health Risk Manag</source><year>2005</year><volume>1</volume><fpage>263</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">17315599</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raveendran</surname><given-names>G</given-names></name><name><surname>Ting</surname><given-names>HH</given-names></name><name><surname>Best</surname><given-names>PJ</given-names></name><name><surname>Holmes</surname><given-names>DR</given-names><suffix>Jr</suffix></name><name><surname>Lennon</surname><given-names>RJ</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction</article-title><source>Mayo Clin Proc</source><year>2007</year><volume>82</volume><fpage>196</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">17290727</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boersma</surname><given-names>E</given-names></name><name><surname>Harrington</surname><given-names>RA</given-names></name><name><surname>Moliterno</surname><given-names>DJ</given-names></name><name><surname>White</surname><given-names>H</given-names></name><name><surname>Théroux</surname><given-names>P</given-names></name><name><surname>Van de Werf</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>189</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">11812552</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>KM</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Neumann</surname><given-names>FJ</given-names></name><name><surname>Montalescot</surname><given-names>G</given-names></name><name><surname>Miller</surname><given-names>DP</given-names></name><etal></etal></person-group><article-title>Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>37</volume><fpage>2059</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">11419888</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><article-title>Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study</article-title><source>Lancet</source><year>1997</year><volume>349</volume><fpage>1429</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">9164316</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vorchheimer</surname><given-names>DA</given-names></name><name><surname>Badimon</surname><given-names>JJ</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name></person-group><article-title>Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease</article-title><source>JAMA</source><year>1999</year><volume>281</volume><fpage>1407</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">10217057</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurm</surname><given-names>HS</given-names></name><name><surname>Smith</surname><given-names>DE</given-names></name><name><surname>Collins</surname><given-names>JS</given-names></name><name><surname>Share</surname><given-names>D</given-names></name><name><surname>Riba</surname><given-names>A</given-names></name><name><surname>Carter</surname><given-names>AJ</given-names></name><etal></etal></person-group><article-title>Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: Insights from a large regional registry of contemporary percutaneous coronary intervention</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>51</volume><fpage>529</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">18237680</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horne</surname><given-names>BD</given-names></name><name><surname>Knight</surname><given-names>S</given-names></name><name><surname>May</surname><given-names>HT</given-names></name></person-group><article-title>Panoptic total cardiovascular risk prediction using all predictors versus optimized risk assessment using variable subsets</article-title><source>Future Cardiol</source><year>2012</year><volume>8</volume><fpage>765</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">23013127</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleiman</surname><given-names>NS</given-names></name><name><surname>Lincoff</surname><given-names>AM</given-names></name><name><surname>Flaker</surname><given-names>GC</given-names></name><name><surname>Pieper</surname><given-names>KS</given-names></name><name><surname>Wilcox</surname><given-names>RG</given-names></name><name><surname>Berdan</surname><given-names>LG</given-names></name><etal></etal></person-group><article-title>Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators</article-title><source>Circulation</source><year>2000</year><volume>101</volume><fpage>751</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10683348</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><collab>ESPRIT Investigators</collab><article-title>Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial</article-title><source>Lancet</source><year>2000</year><volume>356</volume><fpage>2037</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">11145489</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeymer</surname><given-names>U</given-names></name><name><surname>Zahn</surname><given-names>R</given-names></name><name><surname>Schiele</surname><given-names>R</given-names></name><name><surname>Jansen</surname><given-names>W</given-names></name><name><surname>Girth</surname><given-names>E</given-names></name><name><surname>Gitt</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: Results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial</article-title><source>Eur Heart J</source><year>2005</year><volume>26</volume><fpage>1971</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15857851</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dery</surname><given-names>JP</given-names></name><name><surname>Campbell</surname><given-names>ME</given-names></name><name><surname>Mathias</surname><given-names>J</given-names></name><name><surname>Pieper</surname><given-names>KS</given-names></name><name><surname>Harrington</surname><given-names>RA</given-names></name><name><surname>Madan</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>ESPRIT Investigators. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial</article-title><source>Catheter Cardiovasc Interv</source><year>2007</year><volume>70</volume><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17203469</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marmur</surname><given-names>JD</given-names></name><name><surname>Poludasu</surname><given-names>S</given-names></name><name><surname>Lazar</surname><given-names>J</given-names></name><name><surname>Cavusoglu</surname><given-names>E</given-names></name></person-group><article-title>Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention</article-title><source>Catheter Cardiovasc Interv</source><year>2009</year><volume>73</volume><fpage>214</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">19156882</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Shea</surname><given-names>JC</given-names></name><name><surname>Hafley</surname><given-names>GE</given-names></name><name><surname>Greenberg</surname><given-names>S</given-names></name><name><surname>Hasselblad</surname><given-names>V</given-names></name><name><surname>Lorenz</surname><given-names>TJ</given-names></name><name><surname>Kitt</surname><given-names>MM</given-names></name><etal></etal></person-group><article-title>ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial) Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: A randomized controlled trial</article-title><source>JAMA</source><year>2001</year><volume>285</volume><fpage>2468</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">11368699</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deibele</surname><given-names>AJ</given-names></name><name><surname>Jennings</surname><given-names>LK</given-names></name><name><surname>Tcheng</surname><given-names>JE</given-names></name><name><surname>Neva</surname><given-names>C</given-names></name><name><surname>Earhart</surname><given-names>AD</given-names></name><name><surname>Gibson</surname><given-names>CM</given-names></name></person-group><article-title>Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: The Intracoronary Eptifibatide (ICE) Trial</article-title><source>Circulation</source><year>2010</year><volume>121</volume><fpage>784</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">20124127</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Midei</surname><given-names>MG</given-names></name><name><surname>Coombs</surname><given-names>VJ</given-names></name><name><surname>Lowry</surname><given-names>DR</given-names></name><name><surname>Drossner</surname><given-names>MN</given-names></name><name><surname>Prewitt</surname><given-names>KC</given-names></name><name><surname>Wang</surname><given-names>JC</given-names></name><etal></etal></person-group><article-title>Clinical outcomes comparing eptifibatide and abciximab in ST elevation acute myocardial infarction patients undergoing percutaneous coronary interventions</article-title><source>Cardiology</source><year>2006</year><volume>107</volume><fpage>172</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16940721</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saghaei</surname><given-names>M</given-names></name></person-group><article-title>Random allocation software for parallel group randomized trials</article-title><source>BMC Med Res Methodol</source><year>2004</year><volume>4</volume><fpage>26</fpage><pub-id pub-id-type="pmid">15535880</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biondi-Zoccai</surname><given-names>GG</given-names></name><name><surname>Valgimigli</surname><given-names>M</given-names></name><name><surname>Sheiban</surname><given-names>I</given-names></name><name><surname>Margheri</surname><given-names>M</given-names></name><name><surname>Marzocchi</surname><given-names>A</given-names></name><name><surname>Prati</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: Design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial</article-title><source>J Cardiovasc Med (Hagerstown)</source><year>2008</year><volume>9</volume><fpage>957</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">18695440</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biondi-Zoccai</surname><given-names>GG</given-names></name><name><surname>Sangiorgi</surname><given-names>GM</given-names></name><name><surname>Antoniucci</surname><given-names>D</given-names></name><name><surname>Grube</surname><given-names>E</given-names></name><name><surname>Di Mario</surname><given-names>C</given-names></name><name><surname>Reimers</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Taxus in Real-life Usage Evalutaion Study. Testing prospectively the effectiveness and safety of paclitaxel-eluting stents in over 1000 very high-risk patients: Design, baseline characteristics, procedural data and in-hospital outcomes of the multicenter Taxus in real-life usage evaluation (TRUE) study</article-title><source>Int J Cardiol</source><year>2007</year><volume>117</volume><fpage>349</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">16859781</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldea</surname><given-names>GS</given-names></name></person-group><article-title>Use of heparin-bonded cardiopulmonary bypass circuits with alternatives to standard anticoagulation</article-title><source>Advanced Therapy in Cardiac Surgery</source><year>2003</year><volume>103</volume><fpage>46</fpage></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farb</surname><given-names>A</given-names></name><name><surname>Burke</surname><given-names>AP</given-names></name><name><surname>Kolodgie</surname><given-names>FD</given-names></name><name><surname>Virmani</surname><given-names>R</given-names></name></person-group><article-title>Pathological mechanisms of fatal late coronary stent thrombosis in humans</article-title><source>Circulation</source><year>2003</year><volume>108</volume><fpage>1701</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">14504181</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Grines</surname><given-names>CL</given-names></name><name><surname>Cox</surname><given-names>DA</given-names></name><name><surname>Garcia</surname><given-names>E</given-names></name><name><surname>Tcheng</surname><given-names>JE</given-names></name><name><surname>Griffin</surname><given-names>JJ</given-names></name><etal></etal></person-group><article-title>Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><fpage>957</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">11919304</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Shea</surname><given-names>JC</given-names></name><name><surname>Buller</surname><given-names>CE</given-names></name><name><surname>Cantor</surname><given-names>WJ</given-names></name><name><surname>Chandler</surname><given-names>AB</given-names></name><name><surname>Cohen</surname><given-names>EA</given-names></name><name><surname>Cohen</surname><given-names>DJ</given-names></name><etal></etal></person-group><article-title>ESPRIT Investigators. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention</article-title><source>JAMA</source><year>2002</year><volume>287</volume><fpage>618</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">11829701</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granada</surname><given-names>JF</given-names></name><name><surname>Kleiman</surname><given-names>NS</given-names></name></person-group><article-title>Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: Acute coronary syndromes and elective stenting</article-title><source>Am J Cardiovasc Drugs</source><year>2004</year><volume>4</volume><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">14967064</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Shea</surname><given-names>JC</given-names></name><name><surname>Tcheng</surname><given-names>JE</given-names></name></person-group><article-title>Eptifibatide: A potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa</article-title><source>Expert Opin Pharmacother</source><year>2002</year><volume>3</volume><fpage>1199</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">12150697</pub-id></element-citation></ref></ref-list></back></article>